TOFRANIL Drug Patent Profile

When do Tofranil patents expire, and when can generic versions of Tofranil launch?

Tofranil is a drug marketed by Novartis and Specgx Llc and is included in three NDAs.

The generic ingredient in TOFRANIL is imipramine pamoate. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the imipramine pamoate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tofranil

A generic version of TOFRANIL was approved as imipramine pamoate by HIKMA on April 16^th, 2010.

Summary for TOFRANIL

US Patents:	0
Applicants:	2
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	98
Clinical Trials:	5
Patent Applications:	2,355
DailyMed Link:	TOFRANIL at DailyMed

Recent Clinical Trials for TOFRANIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sheppard Pratt Health System	N/A
Central Michigan University	N/A
Astellas Pharma Inc	N/A

See all TOFRANIL clinical trials

US Patents and Regulatory Information for TOFRANIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TOFRANIL	imipramine hydrochloride	INJECTABLE;INJECTION	011838-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Specgx Llc	TOFRANIL-PM	imipramine pamoate	CAPSULE;ORAL	017090-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Specgx Llc	TOFRANIL	imipramine hydrochloride	TABLET;ORAL	087846-001	May 22, 1984		DISCN	Yes	No

Tofranil Market Dynamics and Financial Trajectory: Imipramine Patent, Generic Competition, and Commercial Outlook

Last updated: August 25, 2026

Tofranil is the former brand name for imipramine, a tricyclic antidepressant marketed originally by Ciba-Geigy and later associated with Novartis. Its commercial value has shifted from branded pharmaceutical sales to low-cost generic supply. The active ingredient has been available for decades, has no meaningful remaining branded exclusivity, and faces competition from generic imipramine hydrochloride and imipramine pamoate products. Financial growth is therefore unlikely to come from conventional price expansion. The main commercial variables are supply continuity, manufacturing concentration, limited-use pediatric enuresis demand, and the declining clinical role of tricyclic antidepressants.

What is Tofranil and how is it used?

Tofranil is the brand name for imipramine, a tricyclic antidepressant. Imipramine hydrochloride is generally supplied as an oral tablet, while imipramine pamoate is supplied in capsule form under the Tofranil-PM name.

The U.S. prescribing information identifies imipramine hydrochloride for:

• Depression symptoms in adults.
• Childhood enuresis, or bed-wetting, in appropriately selected pediatric patients.

Imipramine acts primarily by inhibiting norepinephrine and serotonin reuptake. Its pharmacology also produces anticholinergic, antihistaminic, and alpha-adrenergic effects. Those off-target effects contribute to its tolerability burden and safety restrictions, including cardiac toxicity risk and overdose lethality (DailyMed, 2024a; DailyMed, 2024b).

Which dosage forms and strengths are associated with Tofranil?

Product	Active ingredient	Common dosage form	Historical commercial role
Tofranil	Imipramine hydrochloride	Oral tablets	Original branded product
Tofranil-PM	Imipramine pamoate	Oral capsules	Extended-dose branded formulation
Generic imipramine hydrochloride	Imipramine hydrochloride	Oral tablets	Current principal U.S. supply channel
Generic imipramine pamoate	Imipramine pamoate	Oral capsules	Smaller alternative market

Available strengths and manufacturer portfolios can change as companies discontinue or reintroduce products. The economic market is now defined by generic imipramine rather than by branded Tofranil.

When did Tofranil lose exclusivity?

Tofranil lost meaningful market exclusivity many years ago. Imipramine was first introduced in the 1950s, placing its original composition and product patents far beyond their enforceable terms. No current branded patent estate protects the original active ingredient.

The commercial exclusivity timeline is therefore:

Milestone	Timing	Commercial effect
Initial imipramine development and launch	1950s	Establishment of the Tofranil brand
Original composition and formulation protection	Historical	Expired decades ago
Generic imipramine entry	Historical	Removed branded pricing power
Current market	2024 onward	Generic, mature, low-growth market

The product has no remaining New Chemical Entity exclusivity, orphan-drug exclusivity, pediatric exclusivity, or meaningful patent-based brand protection in the United States.

What patents protect Tofranil and imipramine?

No commercially relevant unexpired U.S. patent estate is known to protect the original Tofranil product or imipramine active ingredient. The relevant historical patents expired long ago.

What is the Orange Book status of Tofranil?

The FDA Orange Book is the principal U.S. reference for approved drug products, therapeutic equivalence evaluations, patent listings, and regulatory exclusivity. Tofranil's market position is not supported by a current Orange Book patent barrier comparable to those protecting newer branded medicines (FDA, 2024a).

Key conclusions are:

• No active composition-of-matter patent protects imipramine.
• No meaningful patent term remains on the original Tofranil formulation.
• No current regulatory exclusivity blocks abbreviated new drug application competition.
• Generic applicants do not face a modern branded patent thicket.

The absence of patents does not guarantee uninterrupted generic availability. It does mean that supply and regulatory economics, rather than intellectual property, determine the product's commercial position.

How strong is the Tofranil patent estate?

The patent estate is commercially weak because it is expired and does not create a current barrier to entry.

Patent estate factor	Assessment
Composition-of-matter protection	Expired
Basic formulation protection	Expired or commercially irrelevant
Method-of-use protection	No meaningful current barrier identified
Manufacturing-process protection	Not a material barrier to generic supply
Orange Book patent leverage	Minimal to none
Paragraph IV litigation exposure	Low
Biosimilar protection	Not applicable
Generic substitution risk	High

Later patents covering a specific manufacturing process, salt, particle size, or delivery system could theoretically exist in a mature molecule's broader patent history. Such patents would not restore the original Tofranil franchise unless they covered an FDA-approved, commercially important product and could be enforced against the relevant generic products. No such current estate is central to Tofranil's U.S. market economics.

Which companies are challenging Tofranil through generic competition?

Generic manufacturers, rather than named branded challengers, control the competitive landscape. U.S. availability has historically included products from companies such as:

• Mallinckrodt or legacy Watson/Actavis operations.
• Mylan and its successor Viatris operations.
• Par Pharmaceutical or Endo-related operations.
• Rising Pharmaceuticals and other limited-scale generic suppliers.
• Authorized or contract-manufactured generic distributors.

Manufacturer participation changes over time. Generic approval records and current marketing status are maintained through FDA databases, including Drugs@FDA and the Orange Book (FDA, 2024b).

Because imipramine is an old molecule, competition is usually based on:

• Manufacturing cost.
• Ability to maintain FDA-compliant production.
• Access to active pharmaceutical ingredient supply.
• Wholesale contracting.
• Product availability in specific tablet strengths.
• Willingness to carry a low-volume product.

Brand-to-generic substitution has already occurred. The relevant competitive question is not whether generics can enter, but whether enough suppliers remain to maintain reliable supply.

What is the financial trajectory for Tofranil?

Tofranil has moved through four commercial phases.

Phase one: branded psychiatric franchise

During the early antidepressant market, Tofranil had meaningful value as one of the first widely used tricyclic antidepressants. Branded pricing and physician familiarity supported revenue before selective serotonin reuptake inhibitors and newer drug classes changed treatment patterns.

Phase two: generic erosion

Generic imipramine entry eliminated most branded pricing power. Pharmacy substitution reduced the role of Tofranil as a standalone revenue product. Revenue shifted from the original innovator to multiple low-price generic suppliers.

Phase three: mature generic product

The current market is mature and likely characterized by low unit growth. Demand persists because some patients respond to tricyclic therapy, some physicians use imipramine for refractory depression, and pediatric enuresis remains a labeled use. The product does not have the growth profile of a protected CNS product.

Phase four: supply-driven economics

The likely financial trajectory is flat to declining in nominal brand value, with periodic price volatility caused by supplier exits, manufacturing interruptions, or low inventory. A mature generic can experience temporary price increases without generating durable franchise growth.

No public financial reporting separates Tofranil revenue from broader company portfolios. Novartis and predecessor companies have not provided a current, standalone Tofranil revenue series in public annual reports. As a result, product-level revenue, market share, gross margin, and net sales cannot be reliably quantified from public issuer disclosures (Novartis, 2024).

How large is the current imipramine market?

The imipramine market is small relative to modern antidepressant categories. It competes with:

• SSRIs such as fluoxetine, sertraline, escitalopram, and paroxetine.
• SNRIs such as venlafaxine and duloxetine.
• Other tricyclic antidepressants, including amitriptyline, nortriptyline, and desipramine.
• Newer branded and generic therapies with more favorable tolerability profiles.
• Non-drug and behavioral interventions for pediatric enuresis.

Its demand base is constrained by adverse effects, overdose risk, drug-drug interactions, and the availability of alternatives. The product's clinical utility is strongest in selected patients rather than in first-line population prescribing.

How does Tofranil compare with competing antidepressants?

Product or class	Patent status	Typical market position	Competitive effect on imipramine
Imipramine/Tofranil	Long expired	Mature generic	Baseline product
Amitriptyline	Long expired	Broad generic use, often pain-related	Competes within tricyclic class
Nortriptyline	Long expired	Generic, sometimes favored for tolerability	Reduces imipramine demand
SSRIs	Mostly generic, some newer products protected	First-line depression treatment	Major substitution pressure
SNRIs	Mixed patent status by product	Depression, anxiety, pain	Substitution pressure
Newer branded antidepressants	Product-specific exclusivity	Differentiated or premium segments	Limits premium positioning

Tofranil does not have a clear clinical or commercial differentiator that would support premium pricing.

What formulation patents protect imipramine?

The original tablet and capsule formulations do not have commercially meaningful active protection. Imipramine hydrochloride and imipramine pamoate are established dosage forms with long generic histories.

Potentially relevant formulation issues include:

• Salt selection.
• Tablet excipients.
• Capsule composition.
• Stability and dissolution specifications.
• Packaging requirements.
• Modified-release or specialty delivery systems.

These attributes can support narrow product-specific approvals, but they do not create broad protection for conventional Tofranil tablets. A company seeking a higher-value reformulation would need a clinically meaningful delivery advantage, such as improved tolerability, lower dosing frequency, or a defined adherence benefit. No such modern reformulation has established a significant Tofranil franchise in the U.S. market.

Are there method-of-use patents for Tofranil?

No current method-of-use patent is central to the commercial market for conventional imipramine. The labeled uses are long established. A new patent could theoretically cover a novel patient population, dosing schedule, combination, or therapeutic application, but such a patent would need to support an FDA-approved product or an enforceable method-of-use claim.

The existing commercial uses do not provide practical exclusivity:

• Depression is a mature indication with extensive generic substitution.
• Pediatric enuresis is an older labeled use with multiple non-drug and drug alternatives.
• Off-label uses generally provide limited patent leverage and limited pricing power.

What is the FDA regulatory status of Tofranil?

Imipramine is an FDA-approved prescription drug. The regulatory market consists primarily of approved generic products rather than an actively promoted originator brand.

FDA-related commercial considerations include:

1. Approval pathway: generic products generally rely on abbreviated new drug applications demonstrating pharmaceutical equivalence and bioequivalence.
2. Therapeutic equivalence: products rated therapeutically equivalent can be substituted under applicable state pharmacy laws.
3. Labeling: manufacturers must maintain labeling consistent with FDA requirements.
4. Safety: tricyclic antidepressant warnings remain relevant, particularly for overdose, suicidality monitoring, cardiovascular effects, and pediatric use.
5. Manufacturing: current good manufacturing practice compliance remains a continuing barrier for small suppliers.

The FDA has not granted current exclusivity that would support premium pricing for conventional imipramine.

What generic entry risks exist for Tofranil?

Generic entry risk is structurally high because the product has no meaningful patent barrier. The more important risk is generic supply contraction.

Downside risks

• Further erosion of branded recognition.
• Low reimbursement and contracting pressure.
• Discontinuation by manufacturers with insufficient volume.
• API supply disruption.
• Product-specific shortages in lower-demand strengths.
• Prescriber substitution to newer antidepressants.
• Reduced pediatric use because of safety and tolerability concerns.

Potential upside factors

• Temporary price increases after supplier exits.
• Stable demand from long-term users.
• Niche demand for patients who respond to imipramine after other therapies fail.
• Continued use in selected enuresis cases.
• Portfolio value for a generic company that already has a compliant manufacturing line.

These upside factors are tactical rather than structural. They do not support a durable high-growth thesis.

Does Tofranil face biosimilar competition?

No. Tofranil contains a chemically synthesized small-molecule active ingredient, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply. Competition occurs through generic-drug approval pathways, principally abbreviated new drug applications under the Federal Food, Drug, and Cosmetic Act.

What patent litigation affects Tofranil?

No major current U.S. patent litigation is associated with the conventional Tofranil or imipramine market. The reasons are straightforward:

• The underlying patents expired decades ago.
• No current originator franchise depends on enforcing Orange Book patents.
• Generic manufacturers face no obvious high-value Paragraph IV battleground.
• The product's revenue base is too small to justify extensive patent litigation in most circumstances.

Any present disputes would more likely involve manufacturing quality, supply contracts, product liability, antitrust claims, or regulatory compliance rather than core composition-of-matter patent infringement.

Are there licensing deals involving Tofranil?

No significant current licensing transaction is publicly associated with Tofranil as a growth asset. Historical rights may have changed through corporate mergers, divestitures, and portfolio transfers, but those transactions do not create current exclusivity.

For a generic company, imipramine could be included in a broader product portfolio or contract-manufacturing arrangement. Its value would depend on operational fit, not on proprietary technology. A standalone acquisition of Tofranil rights would have limited strategic value unless paired with manufacturing capacity, distribution rights, or a broader CNS portfolio.

What geographic markets remain commercially relevant?

The commercial profile differs by region.

Region	Market characteristics
United States	Generic-dominated, low patent risk, reimbursement-sensitive
European Union	Generic substitution and country-specific reimbursement controls
Japan	Mature market with local regulatory and prescribing dynamics
Emerging markets	Potentially broader access demand, but lower prices and fragmented distribution
Global hospital channels	Limited but relevant for established psychiatric medicines

Geographic expansion is unlikely to create high-margin growth. In lower-income markets, imipramine may remain accessible because of its low cost. That can support unit demand but usually limits revenue per prescription.

What manufacturing and intellectual-property barriers remain?

The main barriers are operational:

• Reliable API sourcing.
• Validated formulation and dissolution performance.
• FDA and international manufacturing compliance.
• Stability data.
• Packaging and serialization requirements.
• Distribution economics for low-volume strengths.
• Pharmacovigilance and labeling maintenance.

These barriers can reduce the number of active suppliers even when patents are absent. They do not protect pricing in the same way as enforceable intellectual property. A manufacturer that controls a dependable, compliant supply chain may obtain temporary commercial leverage, but competitors can generally enter if the market supports the cost of approval and production.

What is the outlook for Tofranil revenue and investment value?

The base-case outlook is mature and low growth:

Metric	Outlook
Branded Tofranil revenue	Minimal or declining
Generic imipramine unit demand	Stable to declining
Pricing	Low, with possible supply-driven volatility
Gross margin	Commodity-like and manufacturer-dependent
Patent risk	Low
Regulatory risk	Moderate, centered on compliance and supply
Biosimilar risk	None
New product investment case	Weak without reformulation or combination innovation
Portfolio value	Niche, primarily operational

The product can retain cash-generating value for a generic manufacturer with efficient production and established distribution. It is unlikely to support a premium pharmaceutical valuation, a major licensing payment, or a meaningful patent-based investment thesis.

Key Takeaways

• Tofranil is the legacy brand for imipramine, a long-established tricyclic antidepressant.
• Its original patents and regulatory exclusivities expired decades ago.
• The U.S. market is generic-dominated, with no meaningful current Orange Book patent barrier.
• No biosimilar pathway applies because imipramine is a small molecule.
• Current commercial value depends on manufacturing reliability, distribution, and supply concentration.
• Revenue is likely small, mature, and vulnerable to clinical substitution by SSRIs, SNRIs, and other antidepressants.
• Generic price volatility can occur after supplier exits, but it does not establish durable growth.
• There is no major current patent litigation or high-value licensing thesis tied to conventional Tofranil.
• A commercially meaningful opportunity would require a differentiated reformulation, delivery system, or new clinical use.

FAQs

Is Tofranil still sold under its original brand name?

The commercial market is primarily supplied by generic imipramine products. Brand availability can vary by country and distributor, and the original brand has little current economic importance in the United States.

Is imipramine a controlled substance?

Imipramine is not generally classified as a U.S. controlled substance under the Controlled Substances Act. It remains prescription-only and carries significant safety warnings, particularly in overdose.

Can a generic manufacturer obtain exclusivity for a new imipramine product?

A new product could potentially obtain protection for a qualifying formulation, delivery system, or approved use. Such protection would apply to the specific innovation, not to conventional imipramine tablets broadly.

Why can an old generic drug experience price increases?

Prices can rise when manufacturers discontinue production, API supply contracts, quality problems interrupt production, or only a small number of suppliers remain. These increases are usually supply-driven rather than patent-driven.

Is imipramine commercially stronger for enuresis than for depression?

Its continued use can be relatively more concentrated in selected pediatric enuresis cases than in first-line depression treatment. The overall revenue opportunity remains limited because other therapies and behavioral interventions constrain demand.

References

1. DailyMed. (2024a). Imipramine hydrochloride tablet prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. DailyMed. (2024b). Imipramine pamoate capsule prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/development-approval-process-drugs/orange-book

4. U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

5. Novartis AG. (2024). Annual report 2023. https://www.novartis.com/investors/financial-data/annual-reporting